Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
45 shown of 2,701 total abstracts
  1. Abstract 101832026-09-02 · 19:15 CT · E450
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    G. Curigliano, H. Borghaei, J. Cortes, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  2. Abstract 97632026-09-01 · 14:15 CT · S100A
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    T. Mok, S. Peters, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  3. Abstract 99092026-09-05 · 16:45 CT · S406
    CheckMate-692: Opdivo (nivolumab) maintenance in metastatic melanoma
    S. Tolaney, C. Saura, E. Winer · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  4. Abstract 103262026-09-02 · 16:00 CT · S406
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-473 study)
    H. Rugo, A. Spira, C. Robert · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  5. Abstract 98402026-09-01 · 21:00 CT · Hall B1
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-369
    S. Modi, M. Reck · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  6. Abstract 97672026-09-04 · 14:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-104
    S. Antonia, H. Rugo, N. Rizvi · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  7. Abstract 96332026-09-03 · 13:15 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-366 study)
    S. Antonia, M. Krop, J. Cortes, et al. · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  8. Abstract 97642026-09-03 · 13:15 CT · E450
    Long-term follow-up of Opdivo adjuvant for metastatic melanoma: CheckMate-912
    L. Paz-Ares, J. Cortes · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  9. Abstract 100452026-09-04 · 21:45 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-318 study)
    C. Robert, M. Reck · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  10. Abstract 96252026-09-02 · 16:45 CT · Hall B1
    Long-term follow-up of Opdivo maintenance for metastatic melanoma: CheckMate-704
    A. Spira, H. Borghaei · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  11. Abstract 103692026-09-01 · 14:45 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    M.C. Garassino, S. Peters, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  12. Abstract 104692026-09-03 · 18:15 CT · E450
    CheckMate-572: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    S. Modi, M. Krop, C. Saura, et al. · National Cancer Center Japan
    Poster SessionMelanoma📄🖼️
  13. Abstract 95842026-09-02 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-837 study)
    S. Peters, M. Reck, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Poster SessionMelanoma📄🖼️
  14. Abstract 103512026-09-02 · 20:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-136
    G. Curigliano, J. Cortes · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  15. Abstract 95752026-09-03 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-18 study)
    E. Winer, M.C. Garassino, M. Reck · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  16. Abstract 97802026-09-05 · 15:45 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-281 study)
    C. Robert, F. Andre · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  17. Abstract 101782026-09-05 · 18:30 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-4
    S. Peters, H. Rugo · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  18. Abstract 98492026-09-05 · 18:00 CT · Hall B1
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-860
    H. Rugo, J. Cortes, H. Borghaei, et al. · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  19. Abstract 99462026-09-01 · 15:15 CT · S100A
    CheckMate-97: Opdivo (nivolumab) adjuvant in metastatic melanoma
    N. Rizvi, S. Modi, M. Krop, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  20. Abstract 99322026-09-01 · 18:00 CT · S406
    KEYNOTE-8: Keytruda (pembrolizumab) 1L in metastatic melanoma
    S. Tolaney, N. Rizvi, G. Curigliano · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  21. Abstract 97292026-09-05 · 20:30 CT · S100A
    Long-term follow-up of Keytruda neoadjuvant for metastatic melanoma: KEYNOTE-415
    C. Saura, M. Reck, S. Antonia, et al. · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  22. Abstract 104142026-09-04 · 15:00 CT · S406
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-138 study)
    S. Modi, T. Mok, M. Reck, et al. · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  23. Abstract 96902026-09-03 · 21:30 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-492 study)
    R. Herbst, S. Modi · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  24. Abstract 104842026-09-01 · 20:30 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-386 study)
    S. Peters, C. Robert, H. Rugo, et al. · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  25. Abstract 101642026-09-01 · 14:45 CT · S406
    CheckMate-638: Opdivo (nivolumab) 2L in metastatic melanoma
    S. Modi, F. Andre, M.C. Garassino, et al. · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
  26. Abstract 104132026-09-01 · 14:00 CT · Hall B1
    CheckMate-847: Opdivo (nivolumab) adjuvant in metastatic melanoma
    T. Mok, M.C. Garassino, A. Spira · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  27. Abstract 95312026-09-02 · 19:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-758
    C. Robert, S. Peters · MD Anderson Cancer Center
    Poster SessionMelanoma📄🖼️
  28. Abstract 103782026-09-03 · 18:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-676
    F. Andre, E. Winer, A. Spira, et al. · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  29. Abstract 95082026-09-04 · 20:45 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-148 study)
    M.C. Garassino, S. Modi, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Poster SessionMelanoma📄🖼️
  30. Abstract 97342026-09-04 · 20:30 CT · Hall B1
    CheckMate-742: Opdivo (nivolumab) adjuvant in metastatic melanoma
    J. Cortes, A. Spira, S. Antonia · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  31. Abstract 99102026-09-01 · 16:00 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 1L for metastatic melanoma: KEYNOTE-995
    S. Peters, G. Curigliano, S. Modi, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  32. Abstract 99112026-09-01 · 15:15 CT · E450
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-775 study)
    R. Herbst, L. Paz-Ares, E. Winer · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  33. Abstract 104272026-09-04 · 19:30 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-484
    P. Schmid, J. Cortes · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  34. Abstract 99032026-09-02 · 15:30 CT · E450
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-379
    C. Saura, M. Krop · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  35. Abstract 101632026-09-02 · 15:30 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-727
    S. Antonia, S. Modi · Karolinska Institute
    Poster SessionMelanoma📄🖼️
  36. Abstract 102432026-09-05 · 13:15 CT · Hall B1
    Long-term follow-up of Keytruda maintenance for metastatic melanoma: KEYNOTE-154
    T. Mok, M. Krop, G. Curigliano, et al. · Dana-Farber Cancer Institute
    Poster SessionMelanoma📄🖼️
  37. Abstract 104132026-09-02 · 13:00 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-264 study)
    C. Saura, H. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionMelanoma📄🖼️
  38. Abstract 102412026-09-02 · 13:45 CT · S100A
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-306
    C. Robert, A. Spira, T. Mok · Mayo Clinic
    Poster SessionMelanoma📄🖼️
  39. Abstract 100522026-09-03 · 13:45 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    H. Borghaei, H. Rugo, M. Reck, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionMelanoma📄🖼️
  40. Abstract 98542026-09-03 · 21:00 CT · E450
    Long-term follow-up of Opdivo maintenance for metastatic melanoma: CheckMate-806
    S. Modi, L. Paz-Ares, C. Robert, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionMelanoma📄🖼️
  41. Abstract 101862026-09-01 · 19:00 CT · S100A
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-160 study)
    C. Robert, M. Reck, S. Antonia, et al. · Princess Margaret Cancer Centre
    Poster SessionMelanoma📄🖼️
  42. Abstract 101182026-09-05 · 20:00 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-296
    M. Krop, S. Tolaney, S. Antonia · Royal Marsden Hospital
    Poster SessionMelanoma📄🖼️
  43. Abstract 104272026-09-05 · 13:00 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-410
    S. Modi, P. Schmid, A. Spira, et al. · Stanford Cancer Institute
    Poster SessionMelanoma📄🖼️
  44. Abstract 98342026-09-02 · 16:00 CT · S406
    Long-term follow-up of Opdivo 2L for metastatic melanoma: CheckMate-289
    S. Peters, J. Cortes, T. Mok, et al. · Cleveland Clinic
    Poster SessionMelanoma📄🖼️
  45. Abstract 97822026-09-05 · 14:30 CT · Hall B1
    KEYNOTE-231: Keytruda (pembrolizumab) adjuvant in metastatic melanoma
    S. Tolaney, E. Winer, M. Reck, et al. · Institut Gustave Roussy
    Poster SessionMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.